| Literature DB >> 33200458 |
Sergio Caravita1,2, Claudia Baratto1,3, Fabiano Di Marco4, Alice Calabrese5, Giulio Balestrieri5, Filippo Russo6, Andrea Faini1, Davide Soranna1, Giovanni Battista Perego1, Luigi P Badano1,3, Lorenzo Grazioli6, Ferdinando Luca Lorini6, Gianfranco Parati1,3, Michele Senni5.
Abstract
AIMS: Interstitial pneumonia due to coronavirus disease 2019 (COVID-19) is often complicated by severe respiratory failure. In addition to reduced lung compliance and ventilation/perfusion mismatch, a blunted hypoxic pulmonary vasoconstriction has been hypothesized, that could explain part of the peculiar pathophysiology of the COVID-19 cardiorespiratory syndrome. However, no invasive haemodynamic characterization of COVID-19 patients has been reported so far. METHODS ANDEntities:
Keywords: Acute respiratory distress syndrome; COVID-19; Haemodynamics; Heart failure; Pulmonary hypertension
Mesh:
Year: 2020 PMID: 33200458 PMCID: PMC7753704 DOI: 10.1002/ejhf.2058
Source DB: PubMed Journal: Eur J Heart Fail ISSN: 1388-9842 Impact factor: 17.349
Demographics, anthropometrics and clinical characteristics of COVID‐19 patients with acute respiratory distress syndrome requiring mechanical ventilation, and controls
| COVID‐19 ( | Controls ( |
| |
|---|---|---|---|
| Demographics and anthropometrics | |||
| Age, years | 67 [60–70] | 71 [66–75] | 0.144 |
| Male sex, | 18 (86) | 18 (86) | 1.00 |
| BMI, kg/m2 | 29 [25–31] | 27 [26–33] | 0.783 |
| BMI 25–30 kg/m2, | 9 (43) | 10 (48) | 0.757 |
| BMI ≥30 kg/m2, | 8 (38) | 8 (38) | 1.000 |
| Previous medical history, | |||
| Arterial hypertension | 13 (62) | 17 (81) | 0.171 |
| Diabetes mellitus | 9 (43) | 2 (10) | 0.014 |
| Dyslipidaemia | 3 (14) | 9 (43) | 0.040 |
| Chronic kidney disease | 1 (5) | 0 | 0.312 |
| COPD | 1 (5) | 8 (38) | 0.008 |
| Cerebrovascular disease | 1 (5) | 2 (10) | 0.549 |
| Coronary artery disease | 3 (14) | 6 (29) | 0.259 |
| Heart failure | 0 | 2 (10) | 0.147 |
| Atrial fibrillation | 0 | 4 (19) | 0.036 |
| Immunological disorder | 1 (5) | 0 | 0.312 |
| Smoking habitus | 1 (5) | 1 (5) | 1.000 |
Continuous variables are shown as median [interquartile range].
BMI, body mass index; COPD, chronic obstructive pulmonary disease.
Pharmacological treatment and blood tests at the time of right heart catheterization in COVID‐19 patients (n = 21)
| Medical treatment in the intensive care unit | |
| Antiretroviral agents | 6 (29) |
| Steroids | 15 (71) |
| Antibiotics | 15 (71) |
| Hydroxychloroquine | 6 (29) |
| Low molecular weight heparin | |
| Parenteral anticoagulation | 14 (67) |
| Thromboembolic prophylaxis | 7 (34) |
| Adrenergic agents | |
| Norepinephrine alone | 3 (14) |
| Norepinephrine + adrenaline | 3 (14) |
| Norepinephrine dose (µg/kg/min) | 0.07 [0.04–0.1] |
| Furosemide | 13 (62) |
| Furosemide dose, mg | 40 [30–120] |
| Blood tests | |
| High‐sensitivity troponin, ng/mL | 23 [6–94] |
| Haemoglobin, g/dL | 10.3 [8.6–11.5] |
| Creatinine, mg/dL | 0.8 [0.6–1.1] |
| Azotaemia, mg/dL | 56 [39–82] |
| White blood cells, 103/µL | 10.3 [7.0–15.4] |
| C‐reactive protein, mg/dL | 12.7 [2.7–19.0] |
| Procalcitonin, mg/mL | 0.6 [0.2–1.8] |
| D‐dimer, ng/mL | 1470 [1057–2384] |
| Fibrinogen, mg/dL | 564 [372–681] |
Values are given as n (%), or median [interquartile range].
Echocardiographic data
| COVID‐19 ( | Controls ( |
| |
|---|---|---|---|
| LVEDV, mL | 109 [95–119] | 101 [89–110] | 0.395 |
| LVEF, % | 67 [61–72] | 64 [60–65] | <0.001 |
| IVS thickness, mm | 12 [11–13] | 11 [10–12] | 0.024 |
| PW thickness, mm | 11 [10–11] | 10 [9–11] | 0.045 |
| LV mass, g/m2 | 88 [75–108] | 89 [80–102] | 0.915 |
| LV RWT, cm | 0.46 [0.43–0.54] | 0.40 [0.38–0.44] | 0.008 |
| LV geometry | <0.001 | ||
| Normal geometry | 0 (0) | 14 (66) | |
| Concentric remodelling | 10 (77) | 5 (24) | |
| Concentric hypertrophy | 1 (8) | 2 (10) | |
| Eccentric hypertrophy | 2 (15) | 0 (0) | |
| LAVI, mL/m2 | 24 [22–28] | 30 [27–46] | 0.007 |
| RV basal diameter, mm | 36 [32–38] | 40 [36–43] | 0.151 |
| RV/LV ratio | 0.8 [0.7–0.9] | 0.8 [0.7–1.0] | 0.567 |
| RVEDA, cm2 | 21 [19–23] | 18 [16–22] | 0.249 |
| RV FAC, % | 42 [40–56] | 47 [43–49] | 0.669 |
| TAPSE, mm | 22 [17–26] | 25 [21–27] | 0.463 |
| S′ RV wave, cm/s | 14 [13–16] | 15 [13–15] | 0.481 |
| RAVI, mL/m2 | 21 [15–29] | 32 [18–38] | 0.220 |
Values are given as n (%), or median [interquartile range].
FAC, fractional area change; IVS, interventricular septum; LAVI, left atrial volume index; LV, left ventricle; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; PW, posterior wall; RAVI, right atrial volume index; RV, right ventricle; RVEDA, right ventricular end‐diastolic area; RWT, relative wall thickness; TAPSE, tricuspid annular plane systolic excursion.
Mechanical ventilation characteristics and gas exchange data
| COVID‐19 patients | Control group |
| |
|---|---|---|---|
| Mechanical ventilation | |||
| FiO2, % | 70 [60–80] | – | – |
| PEEP, cmH2O | 11 [8–14] | – | – |
| Peak inspiratory pressure, cmH2O | 28 [25–32] | – | – |
| Plateau pressure, cmH2O | 27 [23–29] | – | – |
| Tidal volume, mL | 470 [360–520] | – | – |
| Respiratory rate, /min | 24 [20–28] | – | – |
| Static lung compliance, mL/cmH2O | 31 [24–42] | – | – |
| Gas exchange | |||
| Arterial pH | 7.40 [7.33–7.44] | – | – |
| PaCO2, mmHg | 57 [43–66] | 39 [36–43] | <0.001 |
| PaO2, mmHg | 74 [69–93] | 89 [76–95] | 0.106 |
| SaO2, % | 95 [93–96] | 96 [94–97] | 0.174 |
| Lactate, mmoL/L | 1.1 [1.0–1.6] | 0.7 [0.6–0.8] | <0.001 |
| PvO2, mmHg | 43 [39–48] | 38 [37–40] | 0.091 |
| SvO2, % | 73 [68–77] | 71 [67–73] | 0.371 |
| PaO2/FiO2, mmHg | 103 [83–153] | 424 [361–451] | <0.001 |
| CaO2, mL/dL | 14.4 [12.8–16.7] | 18.4 [17.4–19.9] | <0.001 |
| CvO2, mL/dL | 11.2 [10.0–12.3] | 13.7 [12.3–14.8] | <0.001 |
| C(a‐v)O2, mL/dL | 3.3 [2.9–3.9] | 4.8 [4.5–5.3] | <0.001 |
Values are given as median [interquartile range].
CaO2, arterial oxygen content; C(a‐v)O2, artero‐venous oxygen difference; CvO2, venous oxygen content; FiO2, inspired oxygen fraction; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; PEEP, positive end‐expiratory pressure; PvO2, venous partial pressure of oxygen; SaO2, arterial oxygen saturation.
Invasive haemodynamic data
| COVID‐19 patients | Control group |
| |
|---|---|---|---|
| Cardiac output and shunt fraction | |||
| Heart rate, bpm | 89 [72–94] | 65 [58–78] | <0.001 |
| Cardiac output, L/min | 7.3 [5.3–8.8] | 4.5 [3.9–5.5] | <0.001 |
| Stroke volume, mL | 83 [68–105] | 69 [59–90] | 0.088 |
| Cardiac index, L/min/m2 | 3.8 [2.7–4.5] | 2.4 [2.1–2.8] | <0.001 |
| Qs/Qt | 0.35 [0.28–0.45] | 0.13 [0.06–0.17] | <0.001 |
| Systemic haemodynamics | |||
| Systolic BP, mmHg | 124 [110–143] | 140 [134–148] | 0.208 |
| Diastolic BP, mmHg | 62 [48–71] | 78 [66–80] | 0.007 |
| Mean BP, mmHg | 82 [70–100] | 101 [90–103] | 0.017 |
| Systemic vascular resistance, WU | 9.5 [8.1–13.0] | 18.4 [14.1–23.2] | 0.014 |
| Pulmonary and right heart haemodynamics | |||
| Systolic PAP, mmHg | 41 [34–48] | 25 [22–34] | <0.001 |
| Diastolic PAP, mmHg | 20 [15–26] | 14 [10–16] | <0.001 |
| Mean PAP, mmHg | 27 [25–33] | 17 [14–21] | <0.001 |
| PAWP, mmHg | 15 [11–18] | 9 [8–13] | 0.012 |
| RAP, mmHg | 11 [9–15] | 5 [4–7] | <0.001 |
| RAP/PAWP | 0.8 [0.7–0.9] | 0.5 [0.4–0.7] | 0.004 |
| PAWP – RAP, mmHg | 3 [2–6] | 4 [3–7] | 0.370 |
| Pulmonary vascular resistance, WU | 1.6 [1.1–2.5] | 1.6 [0.9–2.0] | 0.343 |
| Total pulmonary resistance, WU | 4.0 [3.1–4.7] | 3.9 [2.5–5.3] | 0.537 |
| Diastolic pressure gradient, mmHg | 5 [0–8] | 2 [1–3] | 0.047 |
| Transpulmonary pressure gradient, mmHg | 13 [8–14] | 6 [5–8] | 0.002 |
| Mean PAP ≥25 mmHg | 16 (76) | 4 (19) | <0.001 |
| PVR >3 WU | 0 | 0 | 1.000 |
| Post‐capillary PH | 12 (57) | 4 (19) | 0.011 |
| Isolated post‐capillary PH | 12 | 4 | |
| Combined post‐ and pre‐capillary PH | 0 | 0 |
Values are given as n (%), or median [interquartile range].
BP, blood pressure; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; Qs/Qt, intrapulmonary shunt; RAP, right atrial pressure.
Figure 1Inverse relationship between lung compliance and pulmonary artery wedge pressure (PAWP).
Comparison of the mean value of cardiorespiratory variables in our sample of COVID‐19 patients with the pooled value calculated in acute respiratory distress syndrome patients from the literature
| Studies on ARDS from the literature, | ARDS subjects, | Pooled mean of ARDS patients from the literature | Confidence interval | COVID‐19 patients ( |
| |
|---|---|---|---|---|---|---|
| PaO2/FiO2, mmHg | 43 | 1568 | 127 | 117–138 | 121 ± 47 | 0.560 |
| Qs/Qt | 35 | 1147 | 0.36 | 0.33–0.39 | 0.37 ± 0.11 | 0.815 |
| Static lung compliance, mL/cmH2O | 21 | 528 | 34 | 31–37 | 32 ± 12 | 0.691 |
| PEEP, cmH2O | 33 | 1389 | 10.2 | 9.3–11.2 | 11.1 ± 4.0 | 0.330 |
| Mean PAP, mmHg | 66 | 1832 | 31 | 30–32 | 27 ± 8 | 0.071 |
| PAWP, mmHg | 46 | 1580 | 13 | 12–13 | 16 ± 6 | 0.024 |
| CO, L/min | 16 | 261 | 6.9 | 6.3–7.5 | 7.3 ± 2.3 | 0.411 |
| CI, L/min/m2 | 43 | 1362 | 4.3 | 4.1–4.4 | 3.7 ± 1.1 | 0.024 |
| PVR, WU | 38 | 586 | 2.9 | 2.6–3.2 | 1.7 ± 0.8 | <0.001 |
| PVRI, mmHg/L/min/m2 | 34 | 1351 | 4.6 | 4.1–5.0 | 3.4 ± 1.6 | 0.002 |
| SVR, WU | 18 | 231 | 9.9 | 8.8–11.0 | 11.2 ± 4.3 | 0.182 |
| SVRI, mmHg/L/min/m2 | 17 | 1043 | 17.1 | 15.6–18.6 | 21.9 ± 8.2 | 0.013 |
ARDS, acute respiratory distress syndrome; CI, cardiac index; CO, cardiac output; FiO2, inspired oxygen fraction; PaO2, arterial partial pressure of oxygen; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PEEP, positive end‐expiratory pressure; PVR, pulmonary vascular resistance; PVRI, pulmonary vascular resistance index; Qs/Qt, intrapulmonary shunt; SVR, systemic vascular resistance; SVRI, systemic vascular resistance index.